Axsome's second quarter arrived at a curious inflection: the company is still GAAP-unprofitable on an enlarged cost base, but commercial momentum is the strongest in its history. Total net product revenue of $218.4 million was up 46% year over year, driven by AUVELITY's 51% advance to $180.3 million on the first eight weeks of its June 2026 Alzheimer's disease agitation launch and an early 126% spike in new-to-brand prescriptions in the over-65 segment. The quarter was not a "beat": the story was a new $180 million-plus franchise, three Phase 3 solriamfetol readouts now within twelve months, a PDUFA on AXS-12 narcolepsy set for May 1, 2027, and management's first explicit statement that current cash funds the company into cash-flow positivity. The GAAP loss of $51.3 million, essentially flat versus a year ago, sits in front of a 60% jump in SG&A tied to AUVELITY sales-force expansion and SYMBRAVO's commercial build - costs the market is now underwriting as an investment in a four-product CNS franchise rather than absorbing as a recurring expense. The right question is not whether Axsome grows; it is whether the four-product revenue base, layered onto a $776.6 million trailing twelve-month franchise, generates the operating leverage to reach the cash-flow-positive exit that management has just put on the clock.